The FDA approved Vivjoa (oteseconazole capsules), an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential.
Scynexis Inc.,. announced that the FDA has approved Brexafemme(ibrexafungerp tablets), for oral use in patients with vulvovaginal candidiasis (VVC), also known as vaginal yeast infection.
Scynexis announced the submission of a supplemental New Drug Application (sNDA) to the FDA of an additional indication for Brexafemme (ibrexafungerp tablets) for the prevention of recurrent vulvovaginal candidiasis (RVVC).
Mycovia Pharmaceuticals has submitted its New Drug Application (NDA) for VT 1161 (oteseconazole), an oral antifungal product for the treatment of recurrent vulvovaginal candidiasis (RVVC). Also known as chronic yeast infection, RVVC is a debilitating infectious condition defined as three or more episodes per year.
Mycovia, an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel therapies, announced positive topline results from its two pivotal Phase III VIOLET clinical trials for oteseconazole, its drug candidate for treating patients with recurrent vulvovaginal candidiasis (RVVC).
Scynexis announced that the FDA has accepted the Company’s submission of a supplemental New Drug Application (sNDA) to expand the label of Brexafemme (ibrexafungerp tablets) to include the prevention of recurrent vulvovaginal candidiasis (RVVC).
Scynexis announced the presentation of new positive outcomes in patients with refractory vulvovaginal candidiasis (VVC) treated with oral ibrexafungerp from the ongoing Phase III FURI study.
Mycovia Pharmaceuticals announced positive topline results from its Phase III ultraVIOLET clinical trial for VT 1161 (oteseconazole), its drug candidate for treating patients with recurrent vulvovaginal candidiasis (RVVC).